Treatment with interleukin-2 (IL-2) and interferon (IFN(alpha) (2b)) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse

Bone Marrow Transplantation

Volumn 23, Issue 2, 1999, Pages 169-172

  Vivancos, P ^a   Granena Jr A ^a   Sarra J ^a   Granena A ^a  

^a Institut Clinica Corachan   (Spain)

Author keywords

Hematopoietic progenitor transplantation; Immunotherapy; Toxicity

Indexed keywords

ALPHA2B INTERFERON; CYTOKINE; INTERLEUKIN 2;

ADULT; ANOREXIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; INFANT; INJECTION SITE; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0344959400     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701532     Document Type: Article

References (25)

1. Domzig W, Stadler BM, Herberman RB. Interleukin-2 dependence of natural killer activity. J Immunol 1983; 13: 1823-1841.
2. Smith KA. Interleukin-2: inception, impact and implications. Science 1988; 240: 1169-1176.
3. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated-killer cell phenomenon: lysis of natural killer resistant fresh solid tumour cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-1841.
4. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487-1489.
5. Rosenberg SA. Guest editorial: lymphokine activated killer cells: a new approach to the immunotherapy of cancer. J Natl Cancer Inst 1985; 75: 595-603.
6. Rosenberg SA. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: De Vita VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology, JB Lippincott: Philadelphia, 1986, pp 55-91.
7. Rosenberg S, Mule J, Spiess P et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin-2. J Exp Med 1985; 161: 1169-1188.
8. Eisenthal A, Lafreniere R, Lefor A, Rosenberg SA. The effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res 1987; 47: 2771-2776.
9. Strausser JL, Mazumder A, Grimm EA et al. Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J Immunol 1981; 127: 266-271.
10. Mazumder A, Zhang HZ, Rosenberg SA. Lysis of fresh human solid tumors by autologous activated in vitro with lectins. Cancer Res 1982; 42: 913-918.
11. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 1985; 313: 1485-1492.
12. Lotze MT, Matory YL, Ettinghausen SE et al. In vivo administration of purified human interleukin-2. II: Half life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985; 135: 2865-2875.
13. Lotze MT, Chang AE, Seipp CA et al. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity and histological findings. JAMA 1986; 256: 3117-3124.
14. Lotze MT, Matory YL. Rayner AA et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764-2772.
15. Lotze MT, Custer MC, Rosenberg SA. Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg 1986; 121: 1373-1379.
16. Lotze MT, Muul LM, Chang AE et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 1987; 316: 889-905.
17. Atzpodien J, Kirchner H, Franks CR et al. Outpatient treatment of advanced human cancer using a combination of recombinant interleukin-2 and interferon-2b. Insights into Immunotherapy 1990; 1: 47-49.
18. Atzpodien J, Korfer A, Franks CR et al. Home therapy with recombinant interleukin-2 and interferon-2b in advanced human malignancies. Lancet 1990; 335: 1509-1512.
19. Ackerstein A, Kedar E, Slavin S. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood 1991; 78: 1212-1215.
20. Vivancos P, Grañena A. High-dose of hydroxyurea (HU) followed by BU-CY-conditioned ABMT and interferon (IFN) for CML. Report of two cases of chronic myeloid leukemia 2nd International Conference Chronic Myeloid Leukemia, Bologna, Italy. 1992; 247 (Abstr.).
21. Vivancos P, Grañena A, García J et al. Post-ABMT treatment with high dose of IL-2 and IFN. Results of a phase II study. 19th Annual Meeting of the European Bone Marrow Transplantation. 1993; 123 (Abstr.).
22. Slavin S, Ackerstein A, Naparstek E et al. The graft-versus-leukemia (GVL) phenomenon. Is GVL separable from GVHD? Bone Marrow Transplant 1990; 6: 155-161.
23. Nagler A, Ackerstein A, Or R et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients post-autologous marrow or stem cell transplantation. Blood 1997; 89: 3951-3959.
24. Stoppa AM, Fossat C, Blaise D et al. Interleukin-2 induces chemotactic deficiency in patients with oncohematologic malignancies and autologous bone marrow transplantation. Eur Cytokine Netw 1991; 2: 231-237.
25. Blaise D, Olive D, Stoppa AM et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092-1097.